Onzima Ventures Plc Investment Update and Change of Registered Office
November 11 2016 - 9:16AM
UK Regulatory
TIDMONZ
Onzima Ventures plc
("Onzima" or the "Company")
Investee company N4 Pharma announces latest research results for Nuvec®
Change of registered office
N4 Pharma Limited ("N4 Pharma"), in which Onzima holds a 49% equity stake, has
announced that it has successfully demonstrated in-vitro transfection
efficiency for its Nuvec® DNA vaccine system comparable to industry standard
transfection reagents.
Its latest results show that optimised Nuvec® particles achieved 80-90%
transfection efficiency in HEK 293 cells, the same levels as Lipofectamine
2000.
These results can be found here: http://www.n4pharma.co.uk/download/i/mark_dl/u
/4013008883/4630405716/nuvec%20dna%20transfection%20results%201.pdf
N4 Pharma CEO Nigel Theobald commented:
"Our research on our Nuvec® particles continues to show impressive results.
Lipofectamine is widely used for DNA transfection experiments as it achieves
high levels of in-vitro transfection efficiency however it has been
demonstrated to have negative toxic effects on cells so is not used in
commercial product development for in-vivo administration.
We are continuing to build our evidence on Nuvec towards establishing its
acceptability as an in-vivo delivery vector for DNA and RNA based vaccines. Our
next steps are to compare the toxicity of Nuvec® with lipofectamine® where we
expect to show markedly lower toxicity of our particles making them more
suitable for in-vivo use.
We are clearly able to demonstrate high transfection levels, which opens up the
potential for longer term use of Nuvec® as an in-vivo transfection agent for
DNA vaccines. Our R&D program is designed step by step to build the supporting
case for this application for the nuvec® system.
This latest data represents strong steady progress on the path towards
commercialisation of Nuvec®. We expect further results comparing the toxicity
and transfection efficiency of Nuvec® against a wider range of existing
transfection agents in a range of different cell types, over the next 3 or 4
months including comparison against those vectors already established for
in-vivo use. "
The Company also announces that its registered office has now changed to 6th
Floor, 60 Gracechurch Street, London EC3V 0HR.
For further information please contact:
Onzima Ventures PLC Tel: +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns
Nominated Adviser
Cairn Financial Advisers LLP Tel: +44 (0) 20 7 213 0880
Sandy Jamieson, Liam Murray
Broker
Peterhouse Corporate Finance Limited Tel: +44 (0) 20 7469 0930
Guy Miller, Lucy Williams
END
(END) Dow Jones Newswires
November 11, 2016 09:16 ET (14:16 GMT)
Onzima Ventures (LSE:ONZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onzima Ventures (LSE:ONZ)
Historical Stock Chart
From Apr 2023 to Apr 2024